European ConsorTium Glossary AE / Multiple Sclerosis Consensus Therapy Group / /
IndustryTerm
treatment of MS / placebo / medicinal products / /
MedicalCondition
highly active relapsing-remitting multiple sclerosis / progressive multiple sclerosis / disease / inflammatory processes / inflammatory process / brain infection / neurological disorder / Crohn’s Disease / neurological dysfunction / direct and active JCV infection / clinically isolated syndrome / Pathology Multiple Sclerosis / high disease activity / malignant astrocytoma / Progressive multifocal leukoencephalopathy / autoimmune disease / subsequent demyelination / both acute inflammatory events / Multiple Sclerosis / demyelination / Multiple Sclerosis A / acute inflammatory events / inflammation / MS / /
Organization
Food and Drug Administration / European Medicines Agency / United States VAS / Benefit-Risk Analysis BRAT Benefit-Risk Action Team CHMP Committee for Medicinal Products / European Commission / Europeans Medicines Agency / FDA / Committee for Medicinal Products for Human Use / European Union / /
Person
Isabelle Stoeckert / Richard Nixon / Andrew Thomson / Nan Wang / Rick Hermann / Dave Gelb / Alain Micaleff / Silvia Kuhls / Kimberley Hockley / Adam Elmachtoub / /
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and